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Key questions
What is already known about this subject?
 ► Up to 50% of patients with coronary artery disease 
(CAD) may be non-adherent to their secondary pre-
vention medicines (SPMs). This can lead to poor 
control of risk factors, inappropriate therapeutic 
intensification, worse health outcomes, increased 
hospital readmissions and mortality and increased 
healthcare costs. Despite a plethora of research, 
non-adherence remains a key challenge in clinical 
practice. There is a need for a practical approach to 
enable appropriate targeting of interventions.
What does this study add?
 ► Based on a medicines-taking experience self-re-
port, the rate of non-adherence with SPMs in pa-
tients with CAD was consistent with the literature. 
When prompted, patients shared actual and po-
tential modifiable barriers to adherence that could 
be addressed in clinical practice. Non-adherence 
behaviour was selective and was mostly driven by 
forgetfulness, concern about the harm that can be 
caused by SPM and practical barriers.
How might this impact on clinical practice?
 ► Appropriate self-report screening tools can be used 
in clinical practice to identify modifiable barriers to 
adherence among patients with CAD. Healthcare 
professionals should elicit and explore their pa-
tients’ beliefs and experiences with their medicines 
and tailor adherence interventions individually to 
overcome barriers.
AbstrAct
Background Non-adherence to secondary prevention 
medicines (SPMs) among patients with coronary artery 
disease (CAD) remains a challenge in clinical practice. This 
study attempted to identify actual and potential modifiable 
barriers to adherence that can be addressed in cardiology 
clinical practice.
Methods This was a cross-sectional, postal survey-based 
study of the medicines-taking experience of patients 
with CAD treated at a secondary/tertiary care centre. All 
participants had been on SPM for ≥3 months.
Results In total, 696 eligible patients were sent the 
survey and 503 responded (72.3%). The median age was 
70 years, and 403 (80.1%) were male; the median number 
of individual daily doses of all medicines was 6. The rate of 
non-adherence to at least one SPM was 43.5% (n=219), 
but 53.3% of reported non-adherence was to only one 
SPM. Statins contributed to 66.7% and aspirin to 61.7% 
of overall non-adherence identified by the Single Question 
(SQ) tool. In 30.8% of non-adherent patients (n=65), 
this was at least partly intentional. Barriers included 
forgetfulness (84.9%; n=186), worry that medicines will 
do more harm than good (33.8%; n=74), feeling hassled 
about medicines taking (18.7%; n=41), feeling worse 
when taking medicines (14.2%; n=31) and not being 
convinced of the benefit of medicines (9.1%; n=20). In a 
multivariate analysis, modifiable factors associated with 
overall non-adherence included being prescribed aspirin 
(OR: 2.22; 95% CI: 1.18 to 4.17), having specific concern 
about SPM (OR: 1.12; 95% CI: 1.07 to 1.18) and issues 
with repeat prescriptions (OR: 2.48; 95% CI: 1.26 to 4.90). 
Different factors were often associated with intentional 
versus unintentional non-adherence.
Conclusions Using appropriate self-report tools, patients 
share actual and potential modifiable barriers to adherence 
that can be addressed in clinical practice. Non-adherence 
behaviour was selective. Most non-adherence was driven 
by forgetfulness, concern about the harm caused by SPM 
and practical barriers.
IntRoduCtIon
Patients with coronary artery disease (CAD) 
are typically prescribed secondary preven-
tion medicines (SPMs), such as ACE inhibi-
tors, angiotensin receptor blockers (ARBs), 
beta-blockers, statins, oral antiplatelet agents 
and/or aspirin. The benefits of SPMs are well 
established, and their use is recommended in 
national and international guidelines.1–3
However, non-adherence to medicines—
including SPMs—remains a key challenge, 
limiting overall benefits and often leading 
to poor health outcomes, lower quality of 
life and increased demand for healthcare.4–6 
A number of studies have reported high 
levels of non-adherence among patients with 
CAD, typically in the range of 33%–50%.5–10 
Non-adherence to SPMs has been associated 
with a 10%–40% relative increase in the risk 
of cardiac hospitalisation and a 50%–80% 
relative increase in mortality.4 11 12
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Figure 1 Flow diagram of study conduct. A level-1 
medicines review includes screening for any apparent 
problems with prescribed medicines. CAD, coronary 
artery disease; ENCOURAGE, Epidemiology of Northern 
Cardiovascular Outcomes and Underlying Risk of 
Atherosclerosis due to Genes and Environment (programme 
database at the Yorkshire Heart Centre in Leeds, UK); 
GP, general practitioner; NHS, National Health Service; 
RANI-1, First Reported Adherence versus Non-adherence 
Investigation.
A number of factors need to be considered if we are to 
remedy this complex problem in clinical practice.5
First, the medicines-taking experience of patients 
should be routinely explored and modifiable barriers 
addressed.7 Non-adherence is often a hidden problem, 
under-recognised by prescribers and not necessarily 
disclosed by patients.13 Healthcare professionals should 
assess, elicit and explore patients’ beliefs and experi-
ences with their medicines to help them make informed 
choices and address any barriers.5 This requires the use 
of specific tools that can be deployed in clinical practice 
to explore and address barriers to medicines taking.
Second, patient self-reports may be the most useful 
tools for exploring adherence in clinical practice because 
they are inexpensive, pragmatic and more likely than 
other tools to reveal barriers.5 13 Social desirability and 
memory biases may lead to over-reporting of adherence, 
but self-reported non-adherence behaviour is broadly 
considered to be reliable and accurate.13–17
Third, non-adherence may be either intentional or 
unintentional,5 and these should be identified and 
addressed in different ways. Some patients may display 
both types simultaneously.
Fourth, the causes of non-adherence are complex, 
multifactorial and cannot be explained by single fixed 
factors—such as the type or severity of the disease or 
sociodemographics.13 Hence, there is no ‘one size fits all’ 
solution to address non-adherence.13 17–19 The underlying 
causes of non-adherence need to be understood individ-
ually, and interventions tailored to the needs of the indi-
vidual patient.
The great challenge is to implement this in clinical 
practice. Suitable self-report tools are needed that can 
identify actual and potential barriers to SPM adherence 
among patients with ischaemic heart disease. These 
instruments were lacking at the time the present study 
was initiated. Hence, multiple tools were used to assess 
various modifiable barriers to adherence. Understanding 
these barriers, as well as the performance of self-report 
tools in revealing the medicines-related issues faced by 
patients on SPM, will enable interventional studies in a 
clinical setting.
Based on the consideration of the four key factors 
described above, the first Reported Adherence versus 
Non-adherence Investigation (RANI-1) was designed to 
assess adherence rates with SPM among patients with 
CAD and to identify actual and potential modifiable 
barriers to adherence that can be addressed in cardiology 
clinical practice.
MetHods
study design
This was a cross-sectional, survey-based study of the medi-
cines-taking experience of patients with CAD treated at 
the Yorkshire Heart Centre, a secondary/tertiary care 
centre in Leeds, UK. It was performed between January 
2010 and January 2011. A flow diagram summarising the 
study conduct is provided in figure 1. Briefly, potential 
participants were sent a survey (known at that time as the 
Heart Medicines Survey) in the mail, along with explan-
atory information and a consent form, and were invited 
to return the completed materials in a prepaid envelope.
Participants
The survey was sent to patients from the West Yorkshire 
ENCOURAGE (Epidemiology of Northern Cardiovas-
cular Outcomes and Underlying Risk of Atherosclerosis 
due to Genes and Environment) programme who had 
recently expressed an interest in heart-related healthcare 
improvement projects. All had established CAD, defined 
as documented or reported myocardial infarction, angio-
plasty and coronary artery bypass graft, or angina (positive 
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exercise test). Eligible patients had been prescribed at 
least one SPM for ≥3 months.
survey assessments
Baseline data collected for individual patients included 
age, sex, relevant underlying conditions and previous 
procedures, the SPMs prescribed, the number of individual 
daily doses and the number of daily administration times.
The design of the survey itself was guided by a litera-
ture review, which identified several validated adherence 
assessment and exploratory tools. These were assessed for 
feasibility based on the ease of use in daily clinical prac-
tice, ability to identify modifiable barriers to adherence 
and ability to quantify levels of non-adherence. Four were 
included within the survey: the SQ tool,20 the eight-item 
©Morisky Medication Adherence Scale (MMAS-8),21 the 
Adherence Estimator (AE)22 and the Beliefs about Medi-
cines Questionnaire (BMQ).23 Where applicable, permis-
sion from the developers was sought.
The SQ tool asks patients, ‘In the past month, how 
often did you take your medications as the doctor 
prescribed?’.20 The tool was modified by asking partici-
pants to elaborate about individual medications. Scoring 
was based on a 5-point Likert scale (all the time, nearly all 
the time, most of the time, about half the time, less than 
half the time). Due to the low sensitivity of the SQ tool, 
patients were considered non-adherent if they selected 
any answer other than ‘all the time’.
The MMAS-8 uses eight questions to ask patients about 
forgetting to take medicines, not taking medicines for 
reasons other than forgetfulness, changing medicines 
due to feeling unwell or feeling that the condition is 
better controlled and feeling hassled about sticking to 
their treatment plan.21
Participants were asked to answer questions 1–7 as 
‘yes’ or ‘no’; question 8 had a five-point Likert response 
scale (all the time, usually, sometimes, once in a while, 
never/rarely). The scoring was in line with the guidelines 
provided by the author of the tool.
The internal consistency and unidimensionality of 
the construct of the MMAS-8 scale was examined using 
Cronbach’s α statistics and factor analysis to exclude any 
problematic questions and identify multidimensionality. 
Question 5 was excluded because it caused low internal 
consistency. The original author of the MMAS-8 tool was 
contacted and agreed with this exclusion.
Based on the findings of the factor analysis, the results 
from MMAS-8 were subdivided according to factor 1 
questions that focus mainly on unintentional non-adher-
ence (questions 1, 2, 4 and 8) and factor 2 questions that 
focus more on intentional non-adherence (questions 3, 
6 and 7).
The AE is a non-adherence predicting tool, which asks 
patients to assess three statements on a 6-point Likert 
scale (from completely agree to completely disagree)22
1. I worry that my prescription medication will do more 
harm than good.
2. I am convinced of the importance of my prescription 
medication.
3. I feel financially burdened by my out-of-pocket ex-
penses for my prescription medication.
All answers were scored as per guidelines provided by 
the author of the tool.
The BMQ is a tool with 18 questions divided into four 
groups23: the specific necessity for SPM; specific concern about 
SPM; general overuse of medicines and the general harm 
of medicines. Only responses to first two groups of ques-
tions were included in the present analysis. Mean scores 
(ranging from 5 to 25, where 5=strongly disagree and 
25=strongly agree) were calculated for patient beliefs 
about the specific necessity for taking SPM and specific 
concern about taking SPM.
Patients were also asked about potential practical 
barriers to adherence based on whether they had any 
problems with: opening the medicine bottle or blister 
pack, reading the label on the medicine bottle, swallowing 
medicines or getting a repeat prescription. Any patient 
who asked for an alternative was considered to ‘Need a 
solution’, regardless of the extent of the problem.
statistical analysis
A power calculation was used to determine the required 
sample size. A total of 120–180 non-adherent patients 
was considered necessary to detect 1 unit change in 
the MMAS-8 score (based on a power of 90% and 
α=0.05). Levels of non-adherence in the literature are 
33%–50%.5–10 Therefore, screening of 500 patients would 
be more than enough to identify sufficient non-adherent 
patients.
Simple descriptive statistics were used to elucidate the 
characteristics of the patient population and results from 
individual adherence tools.
Statistical analyses were performed using SPSS V.19 
(IBM, Chicago, Illinois, USA). Differences between 
adherent and non-adherent patients were assessed using 
Mann-Whitney U test or independent-samples t-test, or 
χ2 test or Fisher’s exact test, as appropriate. The inde-
pendent-samples t-test was used to compare means 
of parametric data and the Mann-Whitney U test for 
non-parametric or non-normally distributed data. The 
χ2 test or Fisher’s exact test (if less than five cases were 
expected in any cell) were used for categorical data. 
P<0.05 was considered statistically significant.
Multivariate analysis was undertaken using logistic 
regression. Three models were built for the following 
dependent variables: overall non-adherence according to 
MMAS-8 or SQ; factor 1 (unintentional) non-adherence; 
factor 2 (intentional) non-adherence. As recommended 
by statisticians and statistical books,24 25 variables that had 
a p value <0.25 in the univariate analysis for non-adher-
ence were retained to include in the multivariate model. 
A correlation matrix (using Spearman’s coefficient) was 
reviewed for any evidence of collinearity. ORs with 95% 
CIs were calculated.
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Table 1 Patient characteristics
Characteristic
Patients 
(N=503)
Age (years), median (range) 70 (38–92)
Male sex, n (%) 403 (80.1)
Underlying conditions/procedures, n (%)
  Myocardial infarction 349 (69.4)
  Angioplasty 286 (56.9)
  Coronary artery bypass graft 192 (38.2)
  Diabetes* 62 (12.3)
Secondary medicines prescribed, n (%)
  Statin 476 (94.6)
  Aspirin 439 (87.3)
  Beta-blocker 356 (70.8)
  ACE inhibitor 293 (58.3)
  AIIRA 104 (20.7)
  Clopidogrel 59 (11.7)
Total number of medicines†, median (range) 7 (2–20)
Number of individual daily doses, median (range) 6 (1–24)
Number of daily administration times, median (range) 2 (1–4)
Dosing frequency of medicines, n (%)
  All once daily 250 (49.7)
  At least one medicine taken twice daily‡ 189 (37.6)
  At least one medicine taken more than twice daily 64 (12.7)
*Prescribed antidiabetic medication.
†Includes all medicines and not just secondary prevention 
medicines.
‡And no medicines taken more than twice daily.
ACE, angiotensin converting enzyme; AIIRA, angiotensin II 
receptor antagonists.
Table 2 Adherence levels
Adherence Patients
Overall (N=503)
  Adherent 284 (56.5)
  Non-adherent 219 (43.5)
Intentional versus unintentional non-adherence (N=211)
  Factor 1 (unintentional) non-adherence 186 (88.2)
  Factor 2 (intentional) non-adherence 65 (30.8)
  Both factor 1 and 2 non-adherence 40 (19.0)
All data are n (%). Overall adherence was assessed using both 
MMAS-8 and SQ. Intentional and unintentional non-adherence 
was assessed using MMAS-8 only.
MMAS-8, eight-item Morisky Medication Adherence Scale; SQ, 
Single Question.
Results
Patient characteristics
Of the 696 patients who were sent the survey in the mail, 
503 (72.3%) returned the completed questionnaire. The 
demographic profile of these individuals is summarised 
in table 1. The median age was 70 years (range: 38–92), 
and 403 patients (80.1%) were male. The median total 
number of medicines received (including non-SPM) was 
7 (range: 2–20), and the median number of individual 
daily doses was 6 (range 1–24). The median number of 
daily administration times was twice daily (range: 1–4 times 
daily). In total, 27 patients (5.4%) had been on SPM for 
3–12 months; the other 476 (94.6%) had been on at least 
one SPM for >12 months.
levels of adherence
Considering responses to both the MMAS-8 and SQ 
elements of the survey, 56.5% of respondents (n=284/503) 
appeared to be adherent with their medicines, whereas 
43.5% (n=219/503) were non-adherent on one or both 
scales.
The number of SPMs that non-adherent patients failed 
to adhere to was assessed using the modified SQ tool. In 
total, 482 respondents completed this part of the ques-
tionnaire. The sensitivity of the SQ tool to detect non-ad-
herence is low, and hence overall levels of reported 
non-adherence were only 12.5% (n=60/482). However, 
the responses suggested more than half of these patients 
(53.3%; n=32/60) were non-adherent to only one SPM. 
The remainder were non-adherent to two (18.3%; n=11), 
three (11.7%; n=7) or four (16.7%; n=10) SPMs. Among 
these 60 patients, the greatest contributors to overall 
non-adherence were statins (66.7%; n=40), aspirin 
(61.7%; n=37), beta-blockers (30.0%; n=18), ACE inhib-
itors (21.7%; n=13), clopidogrel (6.7%; n=4) and ARBs 
(5.0%; n=3).
The MMAS-8 data were also split according to factor 1 
questions that focused mainly on unintentional non-ad-
herence (eg, forgetfulness) and factor 2 questions that 
focused more on intentional non-adherence (eg, not 
taking medicines because it is a hassle). Among the 211 
non-adherent patients, 88.2% (n=186) displayed factor 
1 (unintentional) non-adherence and 30.8% (n=65) 
showed factor 2 (intentional) non-adherence (table 2).
Reasons for non-adherence
The most common reasons for non-adherence as stated 
by patients were forgetfulness (84.9%; n=186), worry that 
their medicines will do more harm than good (33.8%; 
n=74), feeling hassled about sticking to the treatment 
plan (18.7%; n=41), stopping medicine(s) without telling 
their doctor after feeling worse (14.2%; n=31) and not 
feeling convinced enough about the importance of their 
medicines (9.1%; n=20) (table 3).
Patients were also asked about practical barriers to 
adherence (table 4). In total, 22.4% of patients (n=110) 
reported problems with opening bottles or blister packs, 
8.2% (n=40) had a problem with reading the label, 8.6% 
(n=42) had problems swallowing medicines and 10.4% 
(n=51) had issues with getting repeat prescriptions. 
Problems with reading the label or with getting repeat 
prescriptions were significantly associated with overall 
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Table 3 Reasons of non-adherence among non-adherent 
patients
Reason
Patients 
(N=219)
Forgetfulness of any type 186 (84.9)
Forgetfulness when travelling 26 (11.9)
Worry that their medicines will do more harm than good 74 (33.8)
Hassled about medicines 41 (18.7)
Stopped medicine(s) after feeling worse on medicine* 31 (14.2)
Not convinced enough about the importance of their 
medicines
20 (9.1)
Stopped medicine(s) after feeling condition under control 5 (2.3)
Felt financially burdened by cost of medicines† 11 (29.7)
All data are n (%). Possible reasons for non-adherence were 
assessed based on responses to MMAS-8, SQ and AE. Patients 
could have more than one reason for non-adherence.
*Without telling doctor.
†Among 37 patients who were paying for their prescription(s).
AE, Adherence Estimator; MMAS-8, eight-item Morisky Medication 
Adherence Scale; SQ, Single Question.
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non-adherence. Moreover, all four of the practical prob-
lems assessed were significantly associated with factor 2 
(intentional) non-adherence (table 4).
Beliefs about medicines
Belief about the specific necessity for taking SPMs was lower 
among non-adherent patients than among adherent indi-
viduals (mean score 19.32 vs 18.48, respectively; p=0.016) 
(table 5). In addition, levels of specific concern about taking 
their medicines were higher in non-adherent versus 
adherent patients (mean score 12.70 vs 10.67; p<0.001).
Comparison of adherent and non-adherent patients
Table 6 compares the characteristics of adherent and 
non-adherent patients according to a univariate model. 
Factor 1 (unintentional) non-adherence was associated 
with a number of variables, including younger age, male 
sex, a lower likelihood of diabetes or coronary artery 
bypass graft, fewer medicines and doses per day, a lower 
number of daily administration times and a greater proba-
bility of taking aspirin. Factor 2 (intentional) non-adher-
ence was associated with a younger age, a greater number 
of medicines, a greater probability of taking aspirin and a 
lower probability of taking a beta-blocker.
In a multivariate model, factors significantly associated 
with factor 1 (unintentional) non-adherence included 
younger age, male sex, not being diabetic, no previous 
coronary artery bypass graft, being prescribed aspirin 
and greater specific concerns about their SPM medicines 
(table 7). Factors significantly associated with factor 2 
(intentional) non-adherence included younger age, 
a greater number of prescribed medicines, not being 
prescribed a beta-blocker, being prescribed aspirin, 
lower belief in the specific necessity for their medicines, 
greater specific concerns about their medicines and issues 
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Table 5 Beliefs about medicines among overall adherent and non-adherent patients
BMQ domain Adherent patients Non-adherent patients Mean difference P value
Specific necessity for taking SPM 19.32 (4.10)
(N=281)
18.48 (3.60)
(N=218)
0.85 0.016
Specific concern about taking SPM 10.67 (4.17)
(N=278)
12.70 (4.17)
(N=216)
–2.03 <0.001
Values given for each domain are mean scores (SD). Possible scores range from 5 to 25, where 5=strongly disagree and 25=strongly agree.
BMQ, Beliefs about Medicines Questionnaire; SPM, secondary prevention medicine.
with getting repeat prescriptions. Finally, factors associ-
ated with any non-adherence—whether intentional or 
unintentional—included younger age, male sex, being 
prescribed aspirin, greater specific concern about their 
medicines and issues with getting repeat prescriptions 
(table 7).
dIsCussIon
This study found an overall level of non-adherence with 
SPMs in patients with CAD (43.5%) that was broadly 
consistent with the literature,6–10 although the methods 
used to assess adherence did, of course, differ somewhat 
between studies. Non-adherence was frequently inten-
tional. More than half of non-adherence was to only one 
SPM, suggesting that interventions should target the 
particular drug for which adherence is problematic.
A number of modifiable barriers were identified. 
Among non-adherent patients, the most common under-
lying reasons were forgetfulness (84.9%), worry that their 
SPM medicines will do more harm than good (33.8%) 
and feeling hassled about their medicines (18.7%). 
Many patients had multiple simultaneous barriers. These 
provide an essential framework for designing interven-
tions that can improve adherence. We have shown else-
where that a novel tool, which specifically screens for 
these and other modifiable barriers to adherence, can 
be successfully used in clinical practice—with resulting 
improvements in adherence and outcomes.26
In a multivariate analysis, increasing age and female sex 
were each associated with greater adherence. Previous 
studies have come to varying conclusions on the impact 
of age and sex on adherence.20 27–29 While these factors 
are not modifiable, the uncertain correlation with adher-
ence emphasises the need for clinicians to know their 
patients and tailor adherence interventions individually.
Polypharmacy has been previously identified as a major 
cause of non-adherence.30 However, in the multivariate 
analysis in the present study, taking a greater numbers of 
medicines was not associated with overall non-adherence. 
Better planning of medicines taking may have helped to 
prevent degradation of adherence in patients prescribed 
more drugs.31 Polypharmacy is also a proxy for more 
advanced disease and greater numbers of comorbidi-
ties, which could increase patients’ appreciation of the 
necessity to maintain their health. Indeed, underlying 
diabetes was associated with reduced factor 1 (uninten-
tional) non-adherence in the univariate analysis, which 
is perhaps not surprising given that these patients have 
prior experience of planned medicines taking. Overall, 
polypharmacy per se is not necessarily associated with 
non-adherence. However, polypharmacy was associated 
with factor 2 (intentional) non-adherence behaviours—
such as feeling hassled about sticking to the treatment 
plan or stopping medication due feeling worse when 
taking it. Interventions should, therefore, target the 
particular concerns that patients have about their poly-
pharmacy. Our data align with previous work suggesting 
that poor experiences with treatment may predict 
intentional non-adherence32; by contrast, strong habit 
development (eg, from previous experience of planned 
medicines taking) can predict reduced unintentional 
adherence.
Individual SPMs were associated with variable levels of 
adherence, but only aspirin was identified in the multi-
variate analysis as being significantly associated with 
non-adherence. As identified by the SQ tool, aspirin was 
one of the most non-adhered to SPM, alongside statins. 
However, almost all patients were on statins, and hence 
statin use was not associated with non-adherence in the 
multivariate analysis. The high level of non-adherence to 
aspirin could be due to the familiarity of patients with 
this medicine and greater concern about its gastric side 
effects. Indeed, a review of major news items showed 
that concerns about the side effects of aspirin and statins 
were widely reported during the period of the study. 
With regard to statins, simvastatin and pravastatin (both 
shorter acting compared to atorvastatin and rosuvastatin) 
were the most commonly used agents at the time of the 
survey, both of which should be taken at night. Hence, 
the risk of forgetting these medicines may have been 
elevated among patients taking all other medicines once 
daily.
On the flip side, beta-blockers were associated with 
lower rates of factor 2 (intentional) non-adherence. This 
may have been due to the advice that is repeatedly given to 
patients prescribed beta-blockers (‘Warning: Do not stop 
taking this medicine unless your doctor tells you to stop’) 
or to symptomatic benefits making patients less likely to 
intentionally stop these medicines. In any case, patients 
were clearly selective about which SPMs they adhered to, 
and any interventions should therefore target the specific 
medicine(s) with which they have an issue.
In non-adherent patients, appreciation of the specific 
necessity for taking SPM was lower and specific concern 
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Table 7 Variables significantly associated with non-
adherence in a multivariate logistic regression analysis
Variables associated with non-
adherence OR (95% CI)
Factor 1 (unintentional) non-adherence (N=492)
  Age (per 1 year) 0.96 (0.94 to 0.98)
  Female sex 0.50 (0.29 to 0.82)
  Diabetes 0.44 (0.23 to 0.85)
  Previous coronary artery bypass graft 0.60 (0.40 to 0.90)
  Prescribed aspirin 2.00 (1.05 to 3.85)
  Specific concern about SPM 1.08 (1.03 to 1.13)
Factor 2 (intentional) non-adherence (N=480)
  Age (per 1 year) 0.96 (0.93 to 0.99)
  Number of prescribed medicines (per one 
drug)
1.18 (1.07 to 1.31)
  Prescribed beta-blocker 0.48 (0.25 to 0.90)
  Prescribed aspirin 4.60 (1.25 to 16.96)
  Specific necessity for SPM 0.90 (0.82 to 0.99)
  Specific concern about SPM 1.16 (1.07 to 1.27)
  Issues with repeat prescriptions 3.68 (1.75 to 7.74)
Overall non-adherence (N=484)
  Age (per 1 year) 0.96 (0.94 to 0.98)
  Female sex 0.56 (0.34 to 0.93)
  Prescribed aspirin 2.22 (1.18 to 4.17)
  Specific concern about SPM 1.12 (1.07 to 1.18)
  Issues with repeat prescriptions 2.48 (1.26 to 4.90)
The SPM specific concern and specific necessity is per unit of 
average score according to BMQ scale.
SPM, secondary prevention medicine.
about taking SPM was higher than adherent individuals. 
These factors were also associated with factor 2 (inten-
tional) non-adherence in the multivariate analysis, 
but only specific concern about SPM was associated with 
overall non-adherence. The association of specific concern 
about SPM with factor 1 (unintentional) non-adherence 
suggests that forgetfulness is affected to some extent 
by underlying beliefs about medicines and may not be 
wholly unintentional. This aligns with previous data from 
a study of 24 000 patients with chronic disease, which 
found that greater concern about medication was a signif-
icant predictor of forgetting to take it.33 Lower belief in 
the specific necessity for taking SPM was not associated 
with overall non-adherence but was linked with greater 
intentional non-adherence. This finding is consistent 
with a recent meta-analysis, which found no correlation 
between necessity beliefs and overall medicines adher-
ence among patients with cardiovascular disease.34 The 
authors of the meta-analysis further concluded that the 
relationship between overall medicines adherence and 
concern beliefs is stronger than the relationship between 
adherence and necessity beliefs among patients with 
cardiovascular disease.34 In these patients, alleviating 
concerns may be a more impactful intervention than 
emphasising benefit.
Practical problems with opening medicines’ containers, 
reading labels, swallowing medicines or getting repeat 
prescriptions may also be important contributors to 
non-adherence—in particular to intentional non-adher-
ence. The multivariate analysis demonstrated that diffi-
culties with getting repeat prescriptions had a strong 
association with all types of non-adherence and should 
be a major area for intervention when identified.
Among other factors, angioplasty was associated with 
non-adherence in the univariate (but not the multivar-
iate) analysis. This might have been due to exaggerated 
expected benefits among patients undergoing this proce-
dure.35 36 Perceptions about previous procedures should 
be taken into account when devising interventions.
The cost of medicines is considered to be a potential 
barrier to adherence.5 13 In the present study, prescrip-
tion charges were a reason for non-adherence in almost 
30% of non-adherent patients on whom they were levied, 
although this was a relatively small group. The elimina-
tion of all costs is not necessarily associated with signifi-
cantly improved adherence.37
More generally, the survey used in this study was 
well received by patients and had a high response rate 
(72.3%). This may have been due to its patient-centred 
approach. The detailed responses provided by many indi-
viduals demonstrate a strong interest in talking about 
their medicines, although the recruitment process may 
have identified a particularly highly motivated sample. 
Regardless, the domains explored provided useful prac-
tical information for conducting a patient-tailored medi-
cines review. Qualitative research has suggested that a key 
focus of these interactions should be on improving under-
standing and alleviating concerns about prescribed medi-
cines (with the amount and level of information tailored 
to individual needs), and understanding beliefs around 
the illness and medicines taking to help decide whether 
such factors may influence adherence decisions.38
The various adherence tools used did not provide 
entirely concordant information on propensity for or 
actual non-adherence. Used singly, none of the tools 
would have been sufficient to reveal all the information 
required to facilitate a complete review of patient needs. 
In addition, non-adherence behaviour was not ‘all or 
nothing’ and patients could be adherent to one medicine 
and not others.22 This emphasises the need for health-
care professionals to know their patients and to screen 
frequently for intentional and unintentional non-adher-
ence, including barriers and modifiable factors that can 
lead to this behaviour. Concerns and difficulties with 
taking medicines should be addressed even in patients 
who are apparently adherent.
We must acknowledge some important limitations of 
the present study. Most importantly, it was based on self-re-
ports of adherence; social desirability and memory biases 
may lead to overestimation of adherence by patients. 
However, the adherence rate obtained was broadly in line 
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with previous studies.6–10 In addition, adherence changes 
over time and shifting beliefs about medicines can often 
underlie this: over the first year of treatment, around a 
fifth of patients may experience a significant increase in 
concern about their medicines.39 It would, therefore, be 
valuable to reassess our data over additional time points. 
Finally, this was a single-centre study and hence the results 
may not be applicable across all settings.
Overall, we conclude that, when appropriately 
prompted, patients will share actual and potential modi-
fiable barriers to adherence that can be addressed in clin-
ical practice. Healthcare professionals should elicit and 
explore their patients’ beliefs and experiences with their 
medicines, and tailor adherence interventions individu-
ally to overcome barriers.
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